Tevogen plans to expand TVGN 489's target population to include patients aged 65 and older, enhancing market potential.

A new study has linked the quadrivalent human papillomavirus vaccine to a population health benefit, namely, decrease in anogenital warts. The study results were released at the CDC's 2016 STD ...

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) revealed plans to broaden the scope of its TVGN 489 experimental medication to encompass patients 65 years of age and above. The action expands upon the company ...

Keene State College is making college even more accessible for eligible students through Direct Admission. Students who are the first in their family to earn a four-year degree or are within a ...